Please login to the form below

Not currently logged in
Email:
Password:

neurodegenerative disorders

This page shows the latest neurodegenerative disorders news and features for those working in and with pharma, biotech and healthcare.

GSK supports CEO Emma Walmsley following Elliott's demands for leadership overhaul

GSK supports CEO Emma Walmsley following Elliott's demands for leadership overhaul

Since then, the pharma company announced its first deal following the reveal of its ten-year strategy – a $2.2bn monoclonal antibody (mAb) deal with US biotech Alector in the neurodegenerative ... PGRN regulates immune activity within the brain and

Latest news

More from news
Approximately 1 fully matching, plus 20 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest appointments

  • Azafaros expands executive team with three senior hires Azafaros expands executive team with three senior hires

    Attracting these experienced and skilled executives to the management team of Azafaros is a major step for the company as our lead program AZ-3102 for neurodegenerative lysosomal storage disorders is

  • Pfizer appoints chief scientific officer Pfizer appoints chief scientific officer

    Having first joined Harvard in 1989, Dr Isacson's work in neurogenerative disorders, particularly for Parkinson's disease, has become internationally renowned with his laboratory now one of the leading academic ... Dr Mikael Dolsten, president of

  • Minoyrx Therapeutics appoints chief medical officer Minoyrx Therapeutics appoints chief medical officer

    He joins the Barcelona-based drug development company from Lupin Atlantis Holdings, where he oversaw its clinical strategy and implementation of studies in various therapeutic areas, including neurodegenerative disorders. ... Prior to this, Dr Meya was

  • Chase Pharmaceuticals appoints former Allergan president Chase Pharmaceuticals appoints former Allergan president

    As CEO, Ingram will focus on the direction of Chase Pharmaceuticals' development and commercialisation of improved treatments for neurodegenerative disorders, in particular its current work on symptomatic treatment of Alzheimer's

  • Ex-GSK CEO Jean-Pierre Garnier takes up role at Alzheon Ex-GSK CEO Jean-Pierre Garnier takes up role at Alzheon

    phase III clinical programme targeting a genetically-defined Alzheimer's disease population, and execute on our long-term strategy to bring innovative therapies to patients with neurodegenerative disorders.”.

More from appointments
Approximately 0 fully matching, plus 5 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Jet Off with Maloff Protect

Latest intelligence

Robust Review: COVID19 Assessment
See how our client utilized Rapid Payer Response (RPR) to stay informed and gain continuous insights during the recent global pandemic (COVID19)...
Human behaviour - Sept 21
All change – how untangling human behaviour can encourage better health
Driving better patient outcomes through clear, achievable practical steps that are underpinned by transparent evidence...
Health literacy in the time of COVID-19
In a time when much of the media’s focus is on the ongoing COVID-19 pandemic and the differences in vaccination rates between various regions, countries, and socioeconomic groups, improving health...